Basic Information
| LncRNA/CircRNA Name | AGAP2-AS1 |
| Synonyms | AGAP2-AS1, PUNISHER |
| Region | GRCh38_12:57726271-57728356 |
| Ensemble | ENSG00000255737 |
| Refseq | NR_027032 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | Microarray, qPCR, RNAi, Flow cytometry assay, Cell proliferation assay etc. |
| Sample | glioma tissues, cell lines (LN229 and U87MG) |
| Expression Pattern | up-regulated |
| Function Description | The expression of four lncRNAs in different grades showed that AGAP2-AS1, LINC01198 and MIR155HG were increased with tumor grade, while TPT1-AS1 was decreased. Knockdown of AGAP2-AS1 can inhibit the cell proliferation, migration and invasion, while increase the apoptosis cell rates in vitro. |
| Pubmed ID | 27764782 |
| Year | 2016 |
| Title | LncRNA profile study reveals four-lncRNA signature associated with the prognosis of patients with anaplastic gliomas. |
External Links
| Links for AGAP2-AS1 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |